324 related articles for article (PubMed ID: 26086967)
21. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
[TBL] [Abstract][Full Text] [Related]
22. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
24. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Ceder S; Eriksson SE; Liang YY; Cheteh EH; Zhang SM; Fujihara KM; Bianchi J; Bykov VJN; Abrahmsen L; Clemons NJ; Nordlund P; Rudd SG; Wiman KG
Cell Death Dis; 2021 Jul; 12(7):709. PubMed ID: 34267184
[TBL] [Abstract][Full Text] [Related]
26. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
27. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
Kobayashi T; Makino T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Morii E; Eguchi H; Doki Y
Br J Cancer; 2021 Nov; 125(11):1523-1532. PubMed ID: 34599296
[TBL] [Abstract][Full Text] [Related]
28. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.
Peng X; Zhang MQ; Conserva F; Hosny G; Selivanova G; Bykov VJ; Arnér ES; Wiman KG
Cell Death Dis; 2013 Oct; 4(10):e881. PubMed ID: 24157875
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246.
Haffo L; Lu J; Bykov VJN; Martin SS; Ren X; Coppo L; Wiman KG; Holmgren A
Sci Rep; 2018 Aug; 8(1):12671. PubMed ID: 30140002
[TBL] [Abstract][Full Text] [Related]
30. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Elayapillai S; Ramraj S; Benbrook DM; Bieniasz M; Wang L; Pathuri G; Isingizwe ZR; Kennedy AL; Zhao YD; Lightfoot S; Hunsucker LA; Gunderson CC
Gynecol Oncol; 2021 Jan; 160(1):302-311. PubMed ID: 33131904
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
[TBL] [Abstract][Full Text] [Related]
32. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
[TBL] [Abstract][Full Text] [Related]
33. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
34. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
36. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
38. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
Xie X; He G; Siddik ZH
Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409
[TBL] [Abstract][Full Text] [Related]
39. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Smith JA; Gaikwad A; Ramondetta LM; Wolf JK; Brown J
Gynecol Oncol; 2006 Nov; 103(2):518-22. PubMed ID: 16690105
[TBL] [Abstract][Full Text] [Related]
40. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]